Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects.

A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11

Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest (2004) 3.40

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood (2012) 2.65

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood (2012) 2.27

CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol (2012) 2.05

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol (2013) 1.68

An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. J Med Chem (2006) 1.58

Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood (2013) 1.52

Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol (2012) 1.47

Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology (2012) 1.44

Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas. Haematologica (2013) 1.17

CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther (2013) 1.13

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci (2014) 1.02

XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). J Hematol Oncol (2014) 0.99

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo. J Cancer (2013) 0.94

Perceptions, practices, and consequences associated with foodborne pathogens and the feeding of raw meat to dogs. Can Vet J (2009) 0.92

KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Cancer Chemother Pharmacol (2014) 0.91

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. Oncotarget (2014) 0.90

Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice. Inflamm Res (2009) 0.88

Understanding XPO1 target networks using systems biology and mathematical modeling. Curr Pharm Des (2014) 0.86

Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol (2014) 0.80

Simulation training for surgical residents in pediatric trauma scenarios. Conn Med (2012) 0.78

Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol (2008) 0.77

Comparison of use of the the Airtraq with direct laryngoscopy by paramedics in the simulated airway. Prehosp Emerg Care (2009) 0.77

Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study. Clin Ther (2008) 0.75